PTPN2 and neoplasm: Given our observation of increased antigen presentation in AC484-treated tumour cells both in vitro and in vivo (Fig. 2d–f and Extended Data Fig. 5c), we next evaluated whether inhibition of PTPN2/N1 elicited changes in the peptide repertoire presented on MHC class I molecules of tumour cells.